Partnerships

Bringing the ImmTOR® and ImmTOR-IL precision immune tolerance platform to diverse indications

Why we partner

The potentially broad applicability of the ImmTOR® and ImmTOR-IL™ platform provides the unique ability to address immunogenicity across a range of indications and in combination with a variety of therapeutic approaches. We believe this technology deserves to have a broad patient reach and we are open to developing strategic partnerships, research collaborations and licensing arrangements.

Our Partnerships

Selecta has entered strategic transactions with leading biopharmaceutical companies to further expand our broad and diversified pipeline.

Immtor Approach

Agreement

Indications

2022

Immtor Approach

GENE THERAPY

Agreement

Strategic licensing agreement to develop next-generation AAV Capsids

Indications

Undisclosed

2021

Immtor Approach

BIOLOGIC

Agreement

Strategic licensing agreement to develop targeted, next-generation enzyme therapies

Indications

Undisclosed

2021

Immtor Approach

GENE THERAPY

Agreement

Strategic licensing agreement to enable the dosing of gene therapies

Indications

AAV Mediated Gene Therapies

2021

Immtor Approach

GENE THERAPY

Agreement

Strategic licensing agreement to develop targeted, next-generation gene therapies

Indications

Lysosomal storage disorders

2021

Immtor Approach

AUTOIMMUNE

Agreement

Collaboration to engineer proprietary IL-2 protein agonists

Indications

Autoimmune and deleterious immune indications

2020

Immtor Approach

GENE THERAPY

Agreement

Research Option and License Agreement (Global)

Indications

Duchenne Muscular Dystrophy and certain Limb-Girdle Muscular Dystrophy subtypes

2020

Immtor Approach

BIOLOGIC

Agreement

License Agreement (Global, excluding China)

Indications

Chronic refractory gout

2019

Immtor Approach

GENE THERAPY

Agreement

License Agreement

Indications

Pompe disease

Partner with us

Connect with us about partnership opportunities

We are open to discussing opportunities both for partners to use our ImmTOR® and ImmTOR-ILTM platform for their own therapies as well as for us to bring additional therapies in house. Selecta is also looking for partnerships to unlock the potential of its proprietary IgG protease, Xork, for the mitigation of pre-existing anti-AAV antibodies.